ZETOMIPZOMIB, A FIRST-IN-CLASS SELECTIVE IMMUNOPROTEASOME INHIBITOR, DEMONSTRATES STEROID SPARING BIOCHEMICAL REMISSION IN PATIENTS WITH RELAPSED OR INSUFFICIENTLY RESPONDING AUTOIMMUNE HEPATITIS IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2A STUDY (AASLD 2025) - Oct 8, 2025 - Abstract #0211; P2 | "Pts (N=24, intention-to-to-treat [ITT] population) were randomized (2:1) to zeto 60 mg or PBO s.c. weekly (QW) for 24 Ws in conjunction with 20 – 40 mg prednisone equivalent/day. Zetomipzomib treatment was associated with a favorable safety profile and showed promising efficacy in achieving steroid-sparing CR in a difficult-to-treat population of pts with AIH."
Clinical • P2a data • Autoimmune Hepatitis • Fibrosis • Hepatology • Immunology • Inflammation • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus
|
|
Craig Lammert1; Neel Anand2; David Bade2; Theo Brandt-Sarif2; Shraddha Desai2; Diana Lam2; Tony Muchamuel2; Kiruthi Palaniswamy3; Rachel Peterson2; Kathryn Ray2; Zung To2; Jennifer Whang2; Aparna Goel4
|